$289.52 -0.19 (-0.07%)

Veeva Systems Inc. (VEEV)

Veeva Systems Inc. (VEEV) is a cloud software company that specializes in providing industry-specific solutions for the global life sciences sector. Established in 2007, Veeva offers cloud-based applications for clinical, regulatory, quality, commercial, and data management, helping pharmaceutical and biotech companies streamline operations, improve compliance, and accelerate product development. The company's platform is widely adopted for its ability to enhance efficiency and collaboration within the life sciences industry.

🚫 Veeva Systems Inc. does not pay dividends

Company News

This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy?
The Motley Fool • Cory Renauer • October 16, 2025

Veeva Systems is a software company providing AI-enhanced solutions for pharmaceutical companies, offering tools for drug discovery, clinical trials, and sales processes. The company shows strong growth, profitability, and strategic positioning in integrating AI into healthcare technology.

BlackRock Fund Dividend Reset Offers 9.2% Yield at a Discount
Investing.com • Brett Owens • September 17, 2025

BlackRock Health Sciences Term Trust (BMEZ) recently cut its dividend, but still offers a 9.2% monthly yield. The fund focuses on healthcare innovators that could benefit from potential policy changes, with top holdings in biotech and medical technology companies.

Close-Up International Acquires Pharma CRM Provider MobileDotRep to Expand U.S. Presence and Compete with Veeva and Salesforce
Benzinga • Globe Newswire • September 16, 2025

Close-Up International has acquired MobileDotRep, a pharmaceutical CRM solution provider, to strengthen its U.S. market position and compete with major CRM platforms like Veeva and Salesforce.

Close-Up International Appoints Jim Barone as Executive Vice President of Business Solutions to Continue Launch into US Pharma CRM Market
GlobeNewswire Inc. • Robert Thomas • July 1, 2025

Close-Up International has appointed Jim Barone as Executive Vice President of Business Solutions to expand its presence in the US pharmaceutical CRM market, leveraging his extensive experience in life sciences technology and strategic leadership.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now - Zacks Investment Research
Zacks Investment Research • Zacks Investment Research • July 15, 2024

Veeva Systems is well-positioned for growth due to its strong product portfolio and strategic deals, but faces challenges from stiff competition and data security threats. The company's first-quarter fiscal 2025 performance and growth projections are positive, but rising costs and estimate trends are concerns.

Related Companies